Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis

Fig. 2

Cervical cancers averted by routine one-dose HPV vaccination by country income groups. The lines represent the median projections of the 10 model-country settings: the HSA model in black, HPV-ADVISE model-country pairs in red, and the Harvard model-country pairs in blue. The grey area corresponds to the additional cases averted in the vaccinated cohort after the 100 years of routine vaccination. Cancers averted were discounted at 0%. Only cervical cancers caused by HPV 16, 18, 31, 33, 45, 52, and 58, which could be averted by the 9-valent HPV vaccine, were considered

Back to article page